Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The complex formed by Fel d 1-specific IgE bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the primary molecular trigger for cat-allergic reactions (Source: PubMed, PMID: 30102974). FcεRI is a multimeric receptor that binds the Fc region of IgE antibodies with extremely high affinity, effectively sensitizing the host's immune cells to specific allergens (Source: UniProt P12319). When the major cat allergen, Fel d 1, enters the system, it cross-links these receptor-bound IgE molecules, initiating an intracellular signaling cascade that results in the rapid release of inflammatory mediators such as histamine and leukotrienes (Source: Journal of Allergy and Clinical Immunology, 2016). This degranulation process causes the clinical manifestations of allergy, including rhinoconjunctivitis and asthma. Therapeutic interventions like Omalizumab target this pathway by sequestering free IgE, thereby preventing the formation of the IgE-FcεRI complex (Source: StatPearls, Omalizumab). Additionally, novel monoclonal antibodies like REGN1908 and REGN1909 are designed to bind Fel d 1 directly, preventing it from cross-linking the IgE already present on the receptor surface (Source: Regeneron Pharmaceuticals).
Inhibition of IgE binding to the high-affinity receptor or prevention of allergen-induced receptor cross-linking.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High-affinity immunoglobulin epsilon receptor I (FcεRI) (FcεRI).